findings from the commands study and the approval of luspatercept for lower-risk mds
Published 10 months ago • 76 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
4:35
lower-risk mds in 2021: luspatercept, imetelstat & roxadustat
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:52
investigating luspatercept utilization patterns in lower-risk mds
-
6:37
searching for a career? explore medical research
-
5:19
searching for a career? explore medical research
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
4:36
commands: luspatercept versus epoetin alfa in lr-mds-associated anemia - results & caveats
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
3:19
key clinical trials in mds taking place in the us
-
4:00
real-world data on the efficacy of luspatercept in lr-mds
-
2:33
insights into the results and implications of the commands & imerge studies in lr-mds
-
6:32
luspatercept reduces transfusion burden in mds-related anemia: medalist results
-
4:25
the challenges with accurately diagnosing and risk-stratifying patients with mds
-
2:52
long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
-
2:30
medalist: luspatercept and erythropoiesis biomarkers in mds
-
2:47
molecular background studies to aid diagnosis and treatment of mds
-
1:04
the future of mds management
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?
-
1:44
medalist: episodes of transfusion independence in patients with lr-mds treated with luspatercept